Akeso Inc.

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Jiangsu Hengrui Pharmaceuticals, China’s top innovative drug maker by pipeline size, is set to spring back into the high-stakes arena of global Phase III clinical trials which include sites in the US

As China’s immuno-oncology market adapts to the ever-growing ranks of homegrown PD-1/L1-targeting agents, SinoCellTech has received approval for what will be the 17th product in the sector - but the f

Pfizer/Arvinas’s VERITAC-2 Study Of Vepdegestrant In 2025, the first Phase III clinical readout for a PROTAC degrader is expected in an important milestone for the targeted protein degradation (TPD)